[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655614":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":24,"studyPopulation":24,"armGroups":31,"interventions":43,"overallOfficials":53,"centralContacts":57,"locations":63,"responsibleParty":77,"collaborators":24,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":24,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":24,"enrollmentInfo":88,"targetDuration":24,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":24,"overallStatus":66,"whyStopped":24,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":24},[9],{"measure":10,"description":11,"timeFrame":12},"AUC, zenagamtide, steady state (ss): area under the zenagamtide plasma concentration-time curve during a dosing interval at steady state","Measured as nanomoles per liter hourly (h\\*nmol\u002FL)","From 0 (pre-dose) up to Day 196 and Day 224",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"Cmax, zenagamtide, ss: maximum observed plasma concentration of zenagamtide at steady state","Measured as nanomoles per liter (nmol\u002FL)","From Day 196 to Day 197 and from Day 224 to Day 225",{"measure":19,"description":20,"timeFrame":17},"tmax, zenagamtide, ss: the time to maximum observed plasma concentration of zenagamtide at steady state","Measured as hours",{"measure":22,"description":20,"timeFrame":23},"t1\u002F2, ss; the terminal half-life of zenagamtide after the last dose","From pre-dose on Day 224 until completion of Day 252",null,{"allocation":26,"interventionModel":27,"interventionModelDescription":24,"primaryPurpose":28,"observationalModel":24,"timePerspective":24,"maskingInfo":29},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":30,"maskingDescription":24,"whoMasked":24},"NONE",[32,38],{"label":33,"type":34,"description":35,"interventionNames":36},"Zenagamtide subcutaneous (s.c.)","EXPERIMENTAL","Participants will receive one of the different dose levels of zenagamtide once weekly subcutaneously.",[37],"Drug: Zenagamtide injection",{"label":39,"type":34,"description":40,"interventionNames":41},"Zenagamtide oral","Participants will receive oral dose of zenagamtide once daily.",[42],"Drug: Zenagamtide tablet",[44,49],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":24},"DRUG","Zenagamtide injection","Zenagamtide will be administered to one of the body parts: thigh, abdomen or upper arm",[33],{"type":45,"name":50,"description":51,"armGroupLabels":52,"otherNames":24},"Zenagamtide tablet","Zenagamtide tablet will be taken in the morning in fasted state.",[39],[54],{"name":55,"affiliation":5,"role":56},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[58],{"name":59,"role":60,"phone":61,"phoneExt":24,"email":62},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[64],{"facility":65,"status":66,"city":67,"state":24,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":24},"Charité - Campus Charité Mitte - Charité Research Organisation GmbH","RECRUITING","Berlin","10117","Germany","DE",{"type":72,"coordinates":73},"Point",[74,75],13.41053,52.52437,{"lat":75,"lon":74},{"type":78,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100655614","phase-1-a-research-study-looking-at-the-effect-of-timing-of-meal-after-dosing-and-water-volume-at-dosing-on-how-the-medicine-zenagamtide-is-taken-up-by-the-body-of-participants-with-overweight-or-obesity-100655614",false,"NCT07815067","A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity","Investigating the Effect of Post-dose Meal Timings and Water Volume at Dosing on the Pharmacokinetic Properties of Oral Zenagamtide in Participants With Overweight or Obesity","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator.\n* Unusual meal habits (including, but not limited to, eating disorders) and special diet\n* HbA1c more than or equal to (≥) 6.5 percent (%) \\[48 (nanomoles per mole) mmol\u002Fmol\\] at screening.","ALL","18 Years",{"count":89,"type":90},320,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","The purpose of this clinical study is to test how taking zenagamtide tablets with different meal\u002Fwater variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity. All participants will get zenagamtide.",[96,97],"Overweight","Obesity","2026-10-06",{"date":100,"type":101},"2026-10-07","ACTUAL",{"date":103,"type":101},"2026-09-07",{"date":105,"type":90},"2028-06-12",{"name":5,"class":6},1]